Journal Article

Azithromycin in the Treatment of <i>Legionella</i> Pneumonia Requiring Hospitalization

Joseph F. Plouffe, Robert F. Breiman, Barry S. Fields, Mark Herbert, Jill Inverso, Charles Knirsch, Antonia Kolokathis, Thomas J. Marrie, Lindsay Nicolle and Douglas B. Schwartz

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 37, issue 11, pages 1475-1480
Published in print December 2003 | ISSN: 1058-4838
Published online December 2003 | e-ISSN: 1537-6591 | DOI:
Azithromycin in the Treatment of Legionella Pneumonia Requiring Hospitalization

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Azithromycin is highly active against Legionella pneumophila and has been shown to be efficacious in animal models and in clinical studies of patients with legionnaires disease. This open, prospective, multicenter trial evaluated azithromycin for the treatment of legionnaires disease. Twenty-five hospitalized patients with community-acquired pneumonia and a positive result of a L. pneumophila serogroup 1 urinary antigen assay received monotherapy with intravenous azithromycin (500 mg/day) for 2–7 days, followed by oral azithromycin (1500 mg administered over the course of 3 or 5 days). The mean total duration of intravenous plus oral therapy was 7.92 days. The overall cure rate among clinically evaluable patients was 95% (20 of 21 patients) at 10–14 days after therapy and 96% (22 of 23 patients) at 4–6 weeks after therapy. The results of this study support previously reported data demonstrating that azithromycin is both safe and efficacious for the treatment of hospitalized patients with legionnaires disease.

Journal Article.  4114 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.